Want to see NEOG full AI Analyst Report?
NEOG Stock Chart & Stats
$11.74
-$0.06(-0.64%)
At close: 4:00 PM EDT
$11.74
-$0.06(-0.64%)
Day’s Range― - ―
52-Week Range$5.37 - $14.26
Previous Close$9.34
Volume2.41M
Average Volume (3M)4.62M
Market Cap
$2.54B
Enterprise Value$3.12B
Total Cash (Recent Filing)$172.00M
Total Debt (Recent Filing)$774.20M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Jan 14, 2027EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding218,306,030
10 Day Avg. Volume5,000,587
30 Day Avg. Volume4,620,168
Financial Highlights & Ratios
PEG Ratio2.25
Price to Book (P/B)0.93
Price to Sales (P/S)2.23
P/FCF Ratio60.82
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue3.53
Enterprise Value/Gross Profit7.45
Enterprise Value/Ebitda29.71
Forecast
1Y Price Target
$14.00Price Target Upside19.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.32
Revenue Forecast (FY)$886.61M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelNeogen benefits from repeat testing tied to regulatory standards and customer quality programs. Consumable replenishment can create recurring revenue, while instruments and workflow products support cross-selling and deepen customer relationships over time.
Raised Operating OutlookHigher fiscal-year guidance indicates management sees sufficient commercial traction to support stronger revenue and EBITDA expectations. Planned efficiency programs may also expand margins, improving operating leverage and execution capacity over the next several quarters.
Improving Cash GenerationPositive operating and free cash flow provide internal funding for innovation, technology and operational improvements. The recent cash-generation recovery strengthens financial flexibility, even though sustained conversion will depend on maintaining execution and avoiding renewed volatility.
Bears Say
Persistent UnprofitabilityOngoing net losses and negative EBIT show that revenue has not yet translated into consistent GAAP profitability. This weakens earnings quality, limits internally generated capital, and leaves results more exposed to execution issues or cost increases over the medium term.
Petrifilm Transition Execution RiskThe multi-quarter Petrifilm manufacturing transfer creates a temporary but meaningful execution burden. Duplicative costs and the need to manage customer continuity, suppliers and inventory could pressure margins and working capital before the expected longer-term benefits arrive.
End-market PressurePressure on food and animal safety customers can constrain purchasing activity and delay testing-related decisions. Low U.S. herd levels may also weigh on animal-safety demand, making near-term growth more dependent on international expansion and execution.
Neogen News
NEOG FAQ
What was Neogen Corp’s price range in the past 12 months?
Neogen Corp lowest stock price was $5.37 and its highest was $14.26 in the past 12 months.
What is Neogen Corp’s market cap?
Neogen Corp’s market cap is $2.54B.
When is Neogen Corp’s upcoming earnings report date?
Neogen Corp’s upcoming earnings report date is Jan 14, 2027 which is in 86 days.
How were Neogen Corp’s earnings last quarter?
Neogen Corp released its earnings results on Oct 06, 2026. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.053 by $0.027.
Is Neogen Corp overvalued?
According to Wall Street analysts Neogen Corp’s price is currently Undervalued.
Does Neogen Corp pay dividends?
Neogen Corp does not currently pay dividends.
What is Neogen Corp’s EPS estimate?
Neogen Corp’s EPS estimate is 0.06.
How many shares outstanding does Neogen Corp have?
Neogen Corp has 218,306,030 shares outstanding.
What happened to Neogen Corp’s price movement after its last earnings report?
Neogen Corp reported an EPS of $0.08 in its last earnings report, beating expectations of $0.053. Following the earnings report the stock price went down -2.341%.
Which hedge fund is a major shareholder of Neogen Corp?
Currently, no hedge funds are holding shares in NEOG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neogen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (19.25% Upside)
$14.00 (19.25% Upside)
Blogger Sentiment
Bullish
NEOG Sentiment 80%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 7.2%
Last 30 Days ▲ 23.8%
Last 30 Days ▲ 23.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.78%
12-Months-Change
Fundamentals
Return on Equity
-2.68%
Trailing 12-Months
Asset Growth
-2.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Neogen Corp
Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed. This extensive detection capability covers threats such as foodborne pathogens, spoilage-causing organisms, naturally occurring toxins, food allergens, genetically modified ingredients, ruminant by-products, specific meat identification, residual drugs and pesticides, and overall sanitation issues. A key product is the AccuPoint Advanced rapid sanitation test, which quickly spots adenosine triphosphate (ATP), indicating the presence of living cells, to verify cleanliness. Customers for this segment are diverse, encompassing producers and processors of food and feed, grain operations, manufacturers of processed foods like cookies, crackers, candy, and ice cream, as well as those handling meat, poultry, seafood, fruits, vegetables, and dairy. It also serves laboratories and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety division provides a comprehensive portfolio for the animal health market. Offerings include veterinary instruments, pharmaceuticals, vaccines, topical medications, parasiticides, diagnostic products, rodenticides, cleaning agents, disinfectants, insecticides, and genomics testing services. This segment also supplies specialized products for researchers investigating biologically active substances. Its immunoassay test kits are vital for detecting illicit and therapeutic drugs in farm and racing animals, identifying drug residues in meat and meat products, and assisting in human forensic toxicology drug screenings. Moreover, products from this division are instrumental in upholding hygienic conditions and minimizing the risks posed by bacteria, fungi, and viruses. Neogen Corporation was established in 1981 and is headquartered in Lansing, Michigan.
NEOG Company Deck
NEOG Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive. Neogen reported broad-based revenue growth, improved adjusted EBITDA margins and free cash flow, raised fiscal 2027 guidance, advanced commercial and innovation initiatives, and reached an important Petrifilm validation milestone. Management also highlighted near-term growth timing effects, macroeconomic pressures, transition-related duplicative costs and a full-year EBITDA margin outlook roughly similar to fiscal 2026, but described these issues as understood and incorporated into its plans.View all NEOG earnings summariesNEOG Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$14.00
▲(19.25% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Bio-Rad Laboratories
―
Bruker
―
Pacific Biosciences
―
Quanterix
―
Rapid Micro Biosystems
―
Ownership Overview
0.55% Insiders
28.97% Mutual Funds
0.39% Other Institutional Investors
36.03% Public Companies and
Individual Investors











